Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone and Apalutamide with ADT for Recurrent Prostate Cancer
NCT03777982Phase 3Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2020
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of apalutamide, abiraterone in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Started Apr 2020; status: terminated.
02
Drugs
apalutamideabiraterone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03777982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777982.